Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease
Cadrenal Therapeutics announced plans to submit a request to the FDA for Rare Pediatric Disease Designation for tecarfarin in Kawasaki disease, aiming to serve an underserved pediatric population. If the designation is granted and the drug is approved, the company would be eligible for a Priority Review Voucher, an asset recently valued between $180 million and $205 million in open-market transactions.
Key figures
- Prv value range
- $180 million to $205 million
- Kd incidence multiplier vs west
- 10 to 15 times
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.